203 results on '"Toyota J"'
Search Results
2. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
3. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b
4. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult–to–treat patients with genotype 1 chronic hepatitis C
5. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial
6. Detection of hypermethylation of the p16INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus
7. THE RELATIONSHIP BETWEEN CLINICAL EFFECT OF IFN THERAPY AND SERUM HCV LOAD IN SEROGROUP 2
8. Distribution and changes of FIB-4 index in normal health checkup examinees
9. Determination of the optimum timing of the start of nucleoside analogue by FIB-4 index for hepatitis B patients from the viewpoint of suppressing hepatocarcinogenesis
10. Recurrence of hepatocellular carcinoma in patients with a history of HCC after SVR to DAA for chronic hepatitis C
11. Long-term follow-up of patients with chronic HCV infection treated with daclatasvir-based regimens in phase 2 and 3 studies
12. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: A pooled analysis.
13. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
14. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
15. Long-term follow-up of patients treated with daclatasvir-based regimens in phase 2 and 3 studies
16. Analysis of Hepatitis B Surface Antigen (HBsAg) Levels Using the Highly Sensitive Lumipulse HBsAg-HQ Assay in Hepatitis B Virus Patients with HBsAg Seroclearance According to the Conventional Assay
17. The Real World Experience of Daclatasvir and Asunaprevir Combination Therapy for More Elderly Patients thanthe Clinical Trial Subjects with Genotype 1b Chronic Hepatitis C
18. SAT-099 - Distribution and changes of FIB-4 index in normal health checkup examinees
19. FRI-384 - Recurrence of hepatocellular carcinoma in patients with a history of HCC after SVR to DAA for chronic hepatitis C
20. FRI-330 - Determination of the optimum timing of the start of nucleoside analogue by FIB-4 index for hepatitis B patients from the viewpoint of suppressing hepatocarcinogenesis
21. P0997 : WFA+-M2BP is a predictive factor for fibrosis progression in NAFLD
22. P1216 EFFICACY AND SAFETY OF SIMEPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY IN PATIENTS WITH HCV GENOTYPE 1 – COMPARISON WITH TELAPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY AND PEG-INTERFERON/RIBAVIRIN THERAPY
23. FRI-122 - Analysis of Hepatitis B Surface Antigen (HBsAg) Levels Using the Highly Sensitive Lumipulse HBsAg-HQ Assay in Hepatitis B Virus Patients with HBsAg Seroclearance According to the Conventional Assay
24. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
25. 835 RBV BLOOD CONCENTRATION AT FIRST WEEK OF PEG-IFN/RBV/TVR COMBINATION THERAPY IS A GOOD PREDICTIVE MARKER OF RENAL DYSFUNCTION AND ANEMIA
26. 825 ANALYSIS OF THE OPTIMAL TVR DOSE PER WEIGHT JUDGING FROM ANEMIA DURING PEG-IFN/RBV/TVR COMBINATION THERAPY
27. Virological response and safety of 24‐week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b
28. 14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN
29. 1193 A DESCRIPTION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH DACLATASVIR (BMS-790052) IN COMBINATION WITH RIBAVIRIN AND PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B
30. 1124 2250MG/DAY OF TELAPREVIR DOSAGE IMPAIR THE RIBAVIRIN DOSAGE AND CLINICAL EFFECT OF TRIPLE THERAPY IN THE PATIENTS WITH A LOW TOTAL CLEARANCE OF RIBAVIRIN
31. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult‐to‐treat patients with genotype 1 chronic hepatitis C
32. 1330 IL28B GENOTYPE MAJOR AND RELAPSE OF PREVIOUS PEG-IFN/RBV THERAPY ARE THE CONVINCING PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE IN TELAPREVIR WITH PEG-IFN/RBV THERAPY
33. 268 RELATIONSHIP OF SERUM IP-10 LEVELS WHICH REFLECTS HEPATIC INTERFERON STIMULATING GENE INDUCTION AND ANTIVIRAL EFFECT OF PEG/RBV COMBINATION THERAPY IN PATIENT WITH CHRONIC HEPATITIS C
34. 703 LONG TERM EFFICACY, SAFETY AND RESISTANCE ANALYSES OF ENTECAVIR (ETV) TREATMENT IN JAPANESE NUCLEOSIDE-NAIVE PATIENTS WITH CHRONIC HEPATITIS B (CHB)
35. 799 TIMING OF HCV NEGATIVITY AND POSSIBLE SVR MAY BE PREDICTABLE BY HCVRNA LEVELS MEASURED WITH TAQMAN HCV IN EARLY TREATMENT PHASE
36. Comparison of clinical features of acute hepatitis caused by hepatitis E virus (HEV) genotypes 3 and 4 in Sapporo, Japan
37. Risk Factors for Acute Hepatitis E: a Questionnaire Survey of Patients in Northern Japan
38. P.109 Efficacy and safety of entecavir and lamivudine in japanese adult patients with chronic hepatitis B infection: a phase 2 clinical trial
39. Efficacy of argon plasma coagulation for gastric antral vascular ectasia associated with chronic liver disease
40. Impact of daily high-dose IFNα-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV RNA levels
41. A lineage of hepatitis E virus within genotype IV, associated with severe forms of hepatitis
42. Analysis of the prognosis of hepatocellular carcioma, in terms of the optimal time of live donor liver transplantation
43. Infrequent widespread microsatellite instability in hepatocellular carcinomas.
44. Women's work in Guatemala.
45. Early mutation of precore (A1896) region prior to core promoter region mutation leads to decrease of HBV replication and remission of hepatic inflammation.
46. Gastric varices with splenic vein occlusion treated by splenic arterial embolization.
47. Evaluation of magnetic resonance angiography in detection of gastric varices.
48. Accessory cell function of a human colonic epithelial cell line HT-29 for bacterial superantigens.
49. 586 Optimal dosage of ribavirin during the combination therapy of PEG-IFN α-2b and ribavirin — Search of target concentration of serum ribavirin
50. 498 Efficacy and safety of entecavir in Japanese adult patients with incomplete response to current lamivudine treatment: A phase II clinical trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.